Plain-English translation of NCT06582199 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This research study is looking for biological markers in your blood that could help doctors predict how quickly Alzheimer's disease might progress in each person. The researchers believe that the brain has natural defense mechanisms that resist damage from Alzheimer's disease — a concept called "resilience" — and this study aims to measure those mechanisms. By understanding these biological markers in your blood, doctors may one day be able to personalize treatment and prevention strategies for people in the early stages of cognitive decline.
Current tests for Alzheimer's disease can tell doctors whether the disease process is happening, but they cannot predict how fast it will progress in any individual patient or how the brain is defending itself. This study exists to fill that gap by identifying blood-based markers that reflect the brain's natural resistance to Alzheimer's damage, which could eventually allow doctors to tailor prevention and treatment approaches to each person's unique situation.
You likely qualify if…
You likely don't qualify if…
As a participant, you would donate blood samples that researchers will analyze to identify biological markers related to brain resilience and Alzheimer's disease progression. The study will use advanced computer analysis (machine learning) to process your blood results along with information from your brain imaging and thinking tests. While the trial description does not specify the exact number of visits or duration, you should expect that participation will involve at least one blood draw and possibly follow-up visits for additional testing.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France